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Abstract: In recent decades Chinese medicine has been used worldwide as a complementary
and alternative medicine to treat cancer. Plenty of studies have shown that microRNAs
(miRNAs) play fundamental roles in many pathological processes, including cancer, while
the anti-cancer mechanisms of Chinese medicinal herbs targeting miRNAs also have been
extensively explored. Our previous studies and those of others on Chinese medicinal herbs
and miRNAs in various cancer models have provided a possibility of new cancer therapies,
for example, up-regulating the expression of miR-23a may activate the positive regulatory
network of p53 and miR-23a involved in the mechanism underlying the anti-tumor effect of
berberine in hepatocellular carcinoma (HCC). In this review, we survey the role of Chinese
medicinal herbal products in regulating miRNAs in cancer and the use of mediating miRNAs
for cancer treatment. In addition, the controversial roles of herb-derived exogenous miRNAs
in cancer treatment are also discussed. It is expected that targeting miRNAs would provide
a novel therapeutic approach in cancer therapy by improving overall response and survival
outcomes in cancer treatment, especially when combined with conventional therapeutics and
Chinese medicinal herbal products.
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1. Introduction
With the rapid development of the Human Genome Project, the non-coding sequence that accounts
for 99% of the total human genome is attracting more and more attention by researchers. So far,
in recent decades several kinds of non-coding RNAs have been discovered and identified, including
Piwi-interacting RNAs (piRNAs), short interfering RNAs (siRNAs), small nucleolar RNAs (snoRNAs)
and microRNAs (miRNAs) [1–3]. Among these non-coding RNAs, miRNAs are the most studied ones
in the last years. miRNAs are highly conserved non-coding sequences generally composed of 18–24
nucleotides. They have been shown to be involved in RNA silencing and regulation of the expression of
target genes by attaching to the 31 untranslated region (31 UTR) of target mRNAs. miRNAs are usually
transcribed by RNA polymerase II from their own genes or from introns [4,5]. After transcription as
long primary miRNAs, the double-stranded RNA-binding domain protein DGCR8 and RNase III-like
enzyme Drosha further process the primary miRNAs to shorter hairpin loop structures containing about
70 nucleotides. Then, a protein called Pasha will bind to Drosha to form a microprocessor complex
and cleave the stem-loop structure of the primary miRNAs to form a precursor miRNA (pre-miRNA).
These pre-miRNAs will be exported to the cytoplasm by the nucleocytoplasmic shuttler Exportin-5 and
cleaved by the RNase III enzyme Dicer into mature miRNAs [6–9]. The mature miRNA then combine
with other associated proteins to form the active RNA-induced silencing complex (RISC) and regulate
the target gene expression by recruiting the 31UTR of the target mRNA to RISC. For regulating target
gene expression, miRNA can either degrade the target mRNA or regulate the translation of target mRNA.
As miRNAs are involved in many physiological functions of human cells, the dysregulation of
miRNAs is associated with many kinds of human disorders such as heart and nervous system diseases,
obesity and cancer [10–12]. In particular, many kinds of miRNAs related with the initiation and
progression of cancer have been identified. The oncogenic miRNAs such as miR-155, miR-17-92,
miR-21, miR-221 and miR-222 have been observed to be overexpressed in various malignancies,
while the tumor suppressor miRNAs such as miR-15a/miR-16-1 and let-7 are down-regulated in
cancer [13–15]. Previous studies have proved that miRNAs can affect all six of the hallmarks
of cancer cells: (1) evading growth suppressors (miR-17-92 cluster); (2) self-sufficiency in growth
signals (let-7 family); (3) enabling replicative immortality (miR-372/373 cluster); (4) evasion from
apoptosis (miR-34a); (5) activating invasion and metastases (miR-10b); and (6) inducing angiogenesis
(miR-210) [16]. With the rapid development of genomic technologies such as microarrays, more
and more cancer-related miRNAs have been discovered in various tumor types. Although whether
alterations of miRNA expression is the result of tumoriogenesis or the cause of tumor formation remains
a controversial issue, some basic studies and clinical trials have already demonstrated the potential
prospects of miRNA-based therapeutics in cancer [17,18]. These miRNA-based therapeutics may
be used directly to target tumor cells or to complement other therapies, for example, to reduce the
chemoresistance of cancer cells. The chemosensitization effect of miRNAs has been evidenced by the
silencing of miR-100 and miR-199b-5p in drug-resistant small lung cancer cells and ovarian cancer cells,
respectively [19,20].
Traditional Chinese medicine (TCM) is one of the most widely used adjunctive therapies for cancer
patients worldwide. TCM plays an important role in cancer treatment by suppressing tumor proliferation,
preventing complications, improving quality of life and reducing the side effects of conventional
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treatments in cancer patients [21–23]. So far, studies on the anti-tumor effects of TCM have mainly
focused on screening the effective components from Chinese medicinal herbs and elaborating their
regulatory effects on tumor-related genes and proteins [24,25]. Although research on the role of
Chinese medicinal herbs in regulating non-coding RNAs remains scanty, in recent years more and more
researchers have begun to recognize the importance of the anti-tumor effects of Chinese medicinal herbs
targeting non-coding RNAs such as miRNAs. Herein, we systematically review current studies on the
relationship between miRNAs and anti-tumor TCMs and their active components, to provide a new
aspect of understanding the anti-tumor mechanisms of TCMs. In addition, we discuss a novel hypothesis
of gene regulation mediated by exogenous miRNAs which may provide a brand-new possibility in cancer
therapy by Chinese medicinal herbs.
2. Current Anti-Cancer Research on Chinese Medicinal Herbal Products Targeting miRNAs
2.1. Induction of Apoptosis by Chinese Medicinal Herbal Products Targeting miRNAs in Cancer
Curcumin is the principal curcuminoid of turmeric, which belongs to the ginger family. Curcumin
treatment could result in a >80% knockdown of miR-21 expression in prostate cancer cells, thus
increasing expression of several downstream target genes, including PTEN and PDCD4, and inducing
apoptosis in prostate cancer cells. The in vivo experiment results also confirmed that curcumin could
suppress tumor growth by miR-21-mediated tumor cell apoptosis in a xenograft mice model [26].
Berberine is a famous anti-cancer herbal product from the root of Coptis chinensis. A recent study
has proved that berberine could induce apoptosis in multiple myeloma cells by decreasing the expression
of miR-99a, miR-17 and miR-106 and regulating the TP53, Erb and MAPK signaling pathways [27]. A
study from the same research group found that down-regulating of miR-21 expression by berberine could
also induce multiple myeloma cell apoptosis through the IL6/STAT3 pathways [28]. A Chinese research
group found that camptothecin, which is isolated from the stem and bark of Camptotheca acuminata
could induce apoptosis in cancer cells by down-regulating miR-125b and activation of the mitochondrial
apoptosis pathways by increasing the expression of the Bak1, Mcl1, and p53 genes [29]. MiR-125b
decreased by approximately 55% in both HeLa cells and K562 cells after camptothecin treatment
compared with the control group. Further research demonstrated that miR-125b directly targeted the
31UTR regions of these proapoptotic genes in a camptothecin-induced mitochondrial pathway.
Resveratrol is a popular natural anti-cancer agent isolated from Polygonum cuspidatum and some
fruit skins. Recent studies have found that resveratrol could induce apoptosis by up-regulating miR-137
levels and subsequently reducing EZH2 expression in neuroblastoma. Decreasing EZH2 expression
could further induce H3K27me3 down-regulation and activation of the tumor suppressor genes CLU and
NGFR [30]. In another study, resveratrol induced apoptosis by suppressing miR-21 regulation of BCL-2
protein expression in pancreatic cancer cells [31].
Luteolin is a natural flavone from the leaves of Terminalia chebula. The pro-apoptosis effects of
luteolin in gastric cancer cells are related to down-regulation of Bcl-2 expression by decreasing miR-34a
expression. Further studies showed that anti-miR-34a oligonucleotides could block the luteolin-induced
Bcl-2 suppression in gastric cancer cells [32].
Genistein is a kind of isoflavone which has shown activity inducing apoptosis in prostate cancer
cells. MiR-1260b was down-regulated by more than 50 percent after genistein treatment in prostate
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cancer cells. Knocking down miR-1260b caused inhibition of two target genes, sFRP1 and Smad4. The
expression of these two genes induced apoptosis and reduced survival of prostate cancer cells [33].
Matrine is one of the major bioactive ingredients isolated from Sophora flavescens. The pro-apoptotic
effect of matrine has been identified by many studies. It was found that matrine in combination with
sorafenib could induce apoptosis in HCC cells, and the mechanism study showed that inhibition of
miR-21 and the subsequent increased of PTEN expression contributed to the pro-apoptosis effect of
matrine and sorafenib [34].
2.2. Anti-Metastasis and Anti-Angiogenesis by Chinese Medicinal Herbal Products Targeting miRNAs
in Cancer
The epithelial-mesenchymal transition (EMT) is a process whereby epithelial cells transform into
mesenchymal type ones and become more invasive and migratable. Many studies have confirmed
the relationship between EMT and cancer metastasis [35,36]. Recent research has found that the
expression of several EMT-suppressive miRNAs in colorectal cancer cells was increased by curcumin
treatment. The downstream target genes of these EMT-suppressive miRNAs also decreased by curcumin
treatment thus further inhibited the colorectal cancer cells’ invasion and metastasis [37]. Another study
on curcumin showed its inhibitory activity on the metastasis of melanoma cells through increasing
miR-33b expression and concomitantly suppressing the expression of high-mobility group AT-hook
2(HMGA2) [38]. Resveratrol is also effective in preventing cancer invasion and metastasis. Studies
have shown that resveratrol could suppress the osteosarcoma cell invasion and migration in vitro as well
as lung metastasis in vivo by inhibiting MMP-2 activation. Further mechanistic studies showed that
this MMP-2 inhibition was mediated by miR-328 up-regulation, treatment of osteosarcoma 143B and
U2OS cells with resveratrol (RESV) for 6 h can up-regulate miR-328 expression by approximately
2-fold in both cell lines [39]. Isoflavones isolated from leguminous plants have shown remarkable
anti-invasion and metastasis effects in pancreatic cancer cells. Isoflavone treatment could up-regulate
miR-146a levels and led to suppression of several metastasis- and angiogenesis-related genes such
as IRAK-1, NF-kappaB, EGFR and MTA-2. As isoflavones are nontoxic, they may emerge as new
anti-cancer natural products targeting miRNAs [40]. Panax Notoginseng Saponins (PNS) is the major
class of bioactive ingredients of notoginseng, a herb extensively utilized in TCM for cancer treatment.
PNS treatment could decrease the expression of miR-18a in cancer cells and further down-regulate its
downstream angiogenesis-related genes such as CD34 and vWF. Interestingly, the efficacy of PNS in
cancer therapy is contrary to that seen in heart disease treatment in which PNS up-regulated miR-18a
expression and finally induced angiogenesis [41,42]. For in vivo studies, one recent research report
has found that resveratrol can inhibit tumor metastasis in an immunodeficient mice model. Further
mechanistic studies confirmed that resveratrol can inhibit the mesenchymal-epithelial transition process
by suppressing the expression of FOXC2 through regulation of miRNA-520h-mediated signal cascade
in lung cancer cells [43].
2.3. Proliferation Inhibition by Chinese Medicinal Herbal Products Targeting miRNAs in Cancer
The anti-cancer effects of berberine and Coptidis rhizoma have been extensively elaborated in
our lab. Recently, we have demonstrated that berberine could up-regulate miR-23a expression by
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5-fold compared to the control group and mediate the up-regulation of the tumor suppressive genes
p21/GADD45α and induce G2/M cell cycle arrest in HCC cells [44]. According to our studies, Coptidis
rhizome is also effective in reducing cancer cell proliferation by targeting miRNAs. After treating HCC
cells with Coptidis rhizoma aqueous extract, both miR-21 and miR-23a were obviously up-regulated.
The downstream target genes of these miRNAs still need further exploration in future studies [45].
A group in Italy found that camptothecin, which inhibited the DNA enzyme topoisomerase I, could
suppress the activity ofHIF-1alpha protein by up-regulating miR-17-5p and miR-155 in human cancer
cells, and thus suppress the proliferation activity of cancer cells [46]. Ginsenosides isolated from the
precious Chinese medicine ginseng play an important role in enhancing the immunity of patients with
cancer. The anti-tumor effect in various kinds of tumors of ginsenoside Rh2 has been reported. A recent
study showed that miR-491 plays a key role in inhibiting HCC proliferation by suppressing the epidermal
growth factor receptor (EGFR) signaling pathway, and treatment with ginsenoside Rh2 could up-regulate
miR-491 levels and directly decrease the expression of EGFR [47]. Ginsenoside Rh2 treatment of human
glioma cells could lead to up-regulation of miR-128 level by 3-fold and inhibited tumor proliferation by
decreasing the expression of the miR-128 downstream targeting protein E2F3a [48].
As an anti-cancer alkaloid agent, matrine has been used as effective treatment against breast cancer
with approval by the public health authorities in China. Recent research has shown that matrine
could induce cell cycle arrest at G1/S phase in human breast cancer cells. Further mechanistic
studies demonstrated that matrine could increase PTEN expression by decreasing miR-21 levels which
subsequently led to dephosphorylated Akt, and further induced accumulation of Bad, p27(/KIP1) and
p21(/WAF1/CIP1) [49]. The Chinese herbal formula Aidi Injection has been used as an adjunct
therapy for several kinds of cancers in clinical practice in China. The therapeutic efficacy of Aidi
Injection has been identified by several studies [50–52]. A study using microarray analysis identified
55 down-regulated miRNAs while 45 miRNAs were up-regulated after treatment with Aidi Injection in
breast cancer patients. Further study demonstrated that among these 45 miRNAs, miR-126 could most
remarkably suppress the proliferation of breast cancer cells and 12 downstream target genes of miR-126
were predicted by PicTar and TargetScan software [53]. Epidermal growth factor receptor (EGFR)
plays a crucial role in cancer cell proliferation. Besides the conventional EGFR inhibitors erlotinib
and gefitinib, the herbal flavonoid luteolin showed effect in suppressing EGFR by down-regulating the
Ser/Thr kinase activity of cyclin G-associated kinase (GAK) in prostate cancer cells. According to the
miRNA array analysis, overexpression of miR-630by luteolin may regulate the GAK-EGFR pathway
and induce cell growth arrest [54]. Ganoderma fruiting body has been used as a precious herbal
medicine for thousands years in some Asian countries, but Ganoderma spore lipid was only discovered
and applied in cancer adjunctive therapy several decades ago. Recent studies have demonstrated that
Ganoderma spore lipid inhibited cell proliferation of lung adenocarcinoma in a dose-dependent manner.
Mechanistic studies revealed that Ganoderma spore lipid could inhibit the expression of miR-21 and
obviously increase the expression of PTEN and PDCD4 [55].
The herb mistletoe is widely used in gynecological and obstetrical diseases as well as a
complementary cancer therapy in TCM. The major active component of mistletoe called mistletoe
lectin-I have been shown to display significant proliferation inhibition towards colorectal cancer cells
both in vitro and in vivo. miR-135a and miR-135b were down-regulated by approximately 80% after
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mistletoe lectin-I treatment via degradation of their precursors. Western blot analysis showed that levels
of their their target gene adenomatous polyposis coli (APC) were increased, which contributed to the
anti-proliferative effect displayed by mistletoe lectin-I [56,57].
2.4. Suppression of Cancer Stem-Like Cells by Chinese Medicinal Herbal Products Targeting miRNAs
A novel analog of curcumin has shown inhibitory effect on cancer stem-like cells in chemoresistant
colon cancer cells. A mechanistic study demonstrated that this agent could down-regulate miR-21
expression with up-regulation of PTEN and inhibition of Akt phosphorylation. As the PTEN-Akt
pathway plays an important role in chemoresistance in cancer stem-like cells, this finding may provide
a novel therapeutic agent targeting cancer stem-like cells [58]. Hydroxycamptothecin, a derivative
of camptothecin, is also effective in suppressing cancer stem-like cells. After 72 h treatment with
a low dose of hydroxycamptothecin, the in vivo tumorigenicity of cancer stem-like MHCC97L cells
obviously decreased and the proliferation and invasion ability of these cells were also suppressed.
Further studies showed that miR-122 regulation may participate in the inhibition of cancer-stem like
cells by hydroxycamptochecin, along with suppression of albumin, α-fetoprotein and hepatocyte nuclear
factor-4 expression [59]. Another study in Taiwan found that miR-145 and miR-200 play an important
role in inhibiting the stemness property of nasopharyngeal carcinoma cells after resveratrol treatment.
The herbal agent resveratrol could suppress the stemness and EMT by reactivating p53 and inducing
miR-200 and miR-145 expression [60].
Honokiol is a bioactive ingredient isolated from a number of species of Magnolia. Because of its
special chemical properties and high oral bioavailability, honokiol has been used as a promising herbal
agent for cancer treatment. A study demonstrated that honokiol could increase miR-141 expression and
further down-regulate the target gene zinc finger E-box binding homeobox 2 (ZEB2) in renal cancer cells.
As ZEB2 is associated with cancer stem cell properties and EMT, honokiol could inhibit metastasis as
well as the stem-like properties of cancer cells at least partly through the miR-141/ZEB2 pathway [61].
3. Exogenous miRNAs and Chinese Medical Herbs: A Controversial Hypothesis in
Cancer Treatment
In 2012, an interesting hypothesis on exogenous miRNAs was presented by Zhang et al. According
to their studies, plant-derived miRNAs could transfer into animal’s blood and tissues from food
sources. More surprisingly, their further studies showed that the plant-derived exogenous miR-168 could
down-regulate the expression level of low-density lipoprotein receptor-associated protein 1 in the liver
of mice [62]. Several decades ago, biological researchers believed that extracellular RNAs are unstable
in peripheral blood, so here should not be any exogenous RNA in the serum or tissues of mammals.
But subsequent studies confirmed that miRNAs are highly stable in peripheral blood in mammals, where
they are resistant to the extreme pH and temperature in blood and insensitive to RNase activity [63–65].
These pioneering findings may show that some miRNAs such as viral-derived or herb-derived miRNAs
may transport and function across different species [66,67]. However, so far, only a few positive results
supporting this theory have been published, while several studies have demonstrated the absence of
plant exogenous miRNAs in mammalian blood [68]. Moreover, the reproducibility of Zhang’s results
was recently challenged by several authors. For example, Tosar et al., attributed Zhang’s results
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to an underestimated effect of contamination [69]. These opposing ideas remind us that it is still
too early to draw any conclusions about inhibition of cancer progression by herb-derived exogenous
miRNAs [68,70,71]. In fact, it seems more convincing that miRNAs may act as interactive factors
between heterogeneous cell types in the human body system when using Chinese herbal medicines
to treat cancers. It was found that by treatment with the natural compound epigallocatechin gallate
(EGCG), expression of miR-16 in breast cancer cells-derived exosome can be up-regulated, and this
cancer cell-derived exosome could be absorbed by tumor associated macrophages (TAMs) and lead to
functional alteration of the TAMs [72]. However, Zhang’s theory still deserves further exploration,
followed by elimination of possible contamination and involvement of indirect regulation of Chinese
herbal medicines on endogenous miRNAs, in this case, functional analysis of exogenous miRNAs by oral
intake of miRNA-containing herbal products. This would be a new area with lots of work to do including
profiling endogenous and exogenous miRNAs, identifying the endogenous targets of exogenous miRNAs
and elaborating the possible mechanism(s) of heterogeneous interaction between mRNAs and miRNAs.
4. Conclusions
According to the previous studies, miRNAs target more than 5000 human genes, which represent
probably 30% of the human genome [73]. These single-strand small non-coding RNAs are critically
involved in regulating gene expression and play an important role in the pathogenesis and progression
of many human diseases, including cancer. By regulating their target genes, miRNAs suppress
tumoriogenesis and the progression of cancer by inducing apoptosis, arresting cell cycle, inhibiting
cancer stem-like cells and suppressing metastasis or angiogenesis. Based on our original research
and a literature study, 14 Chinese medical herbal products including herbal isolates, herbal extracts
and herbal compounds can effectively inhibit carcinogenesis, progression and metastasis by targeting
different miRNAs (Table 1). Among these miRNAs regulated by Chinese medical herbal products,
miR-21 was the most reported miRNA that has been extensively studied in various cancers. PTEN and
PDCD4 are the common target genes regulated by miR-21 and both contribute to the anti-cancer effect
of herbal products. Another interesting observation is the regulation of miR-18a in different type of
tissues by the natural agent PNS. PNS treatment could decrease the expression of miR-18a in tumor and
further down-regulate CD34 and vWF that led to angiogenesis inhibition in tumors, while an opposite
activity by PNS on angiogenesis was observed in heart. Besides the regulation of endogenous miRNAs
by Chinese medical herbal products, the exogenous miRNAs derived from herbs also give rise to a
promising hypothesis of the mechanism of action of Chinese herbal medicine for cancer therapy, but
more convincing evidence must be provided to support the therapeutic efficacy by dietary intake of
herbal miRNAs.
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Table 1. Anti-cancer Chinese medicinal herbal products targeting miRNAs.
Chinese Medicinal Herbal Products Cell models Employed miRNAs Effect in Cancer Cells Target Genes Reference
Berberine
Human multiple myeloma cells. miR-99a, miR-17 Induce apoptosis TP53Erb, MAPK [27,28]
SKOV3 cells miR-106, miR-21 IL6/STAT3
HepG2 (p53 wild type), Hep3B (p53-deficient) miR-23a Anti-proliferation Nek6 [44]
Curcumin
DU145 human prostate cancer cells miR-21 Induce apoptosis PTEN, PDCD4 [26]
colon cancer HCT116 and HT-29 cells Anti-cancer stem like cells PTEN-Akt [58]
HCT116 and SW480 CRC cells. MicroRNA-33b Anti-metastasis HMGA2 [37,38]
Camptothecin
HeLa and HEK293 cells miR-155, miR-17-5p Anti-proliferation HIF-1alpha [46]
HeLa cells and PC3 cells miR-125b Induce apoptosis Bak1, Mcl1, p53 [29]
MHCC97 cells miR-122 Anti-cancer stem like cells
albumin, alpha-fetoprotein,
hepatocyte nuclear factor-4
[59]
Resveratrol
Neuro-2a and SH-SY5Y cell line miR-137,miR-21 Induce apoptosis EZH2, BCL-2 [30,31]
HOS, MNNG/HOS, and 143B cells miR-328 Anti-metastasis MMP-2 [39]
TW01, TW06, and HONE-1 cells miR-145, miR-200c Anti-cancer stem like cells P53 [60]
CL1-5, A549, H322 cell lines miRNA-520h Anti-MET process FOXC2 [43]
Ginsenoside
SMMC-7721 cells miR-491 Anti-proliferation EGFR [47]
U251, T98MG and A172 cells miRNA-128 E2F3a. [48]
Luteolin BGC-823 and SGC-7901 cells
miR-34a Induce apoptosis Bcl-2 [32]
miR-630 Anti-proliferation GAK [54]
Isoflavone
Colo357 and Panc-1 cells miR-146a Anti-metastasis
IRAK-1, NF-kappaB,
EGFR, MTA-2.
[40]
PC-3 and DU-145 cells miR-1260b
Anti-proliferation and
induce apoptosis
sFRP1, Smad4. [33]
Matrine
MCF-7 cells miR-21 Anti-proliferation PTEN [49]
HepG2 and Hep3B cells Induce apoptosis [34]
Aidi Injection MCF-7 cells mir-126 Anti-proliferation Undiscovered. [53]
Ganoderma spore lipid SPC-A1 cells miR-21 Anti-proliferation PTEN, PDCD4
PNS Murine lewis lung carcinoma (LLC) cell miR-18a Anti-angiogenesis CD34, vWF
Coptidisrhizoma MHCC97-L cells miR-21, miR-23a Anti-proliferation Undiscovered
Mistletoe lectin-I CLY and HT-29 cells miR-135a, miR-135b Anti-proliferation APC
Honokiol A-498 cells miR-141
Anti-cancer stem like cells
and anti-metastasis
ZEB2
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In conclusion, these Chinese medical herbal products, which have been tested extensively by in vitro
and in vivo studies, have shown encouraging safety profiles and significant anti-cancer effect via
targeting specific miRNAs. Chinese herbal medicines and miRNAs may provide a new possibility for
alternative therapies of cancer. We hope this review on Chinese herbal medicines targeting miRNAs
will contribute to a novel understanding of anti-cancer Chinese herbal medicines and shed light on their
future clinical applications.
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